Orlando, Florida, U.S., November 11, 2026
The Lupus Research Alliance (LRA) has awarded its prestigious 2026 Lupus Insight Prize to Gregory Barton, PhD, of the University of California, Berkeley, and the Howard Hughes Medical Institute, and Olivia Majer, PhD, of Cincinnati Children’s, recognizing their groundbreaking research into the immune-regulatory mechanisms responsible for systemic lupus erythematosus (SLE). The award recognizes their discoveries explaining how UNC93B1, an important immune-regulatory protein, controls Toll-like receptor 7 (TLR7) activity and prevents the immune system from mistakenly attacking healthy tissues. The findings provide important insights into how genetic alterations affecting this regulatory pathway can trigger excessive immune activation and contribute to autoimmune disease development. The researchers received the award during the American College of Rheumatology (ACR) Convergence 2026 meeting in Orlando, Florida, on November 11, 2026. The $100,000 Lupus Insight Prize recognizes significant scientific discoveries with the potential to transform understanding, diagnosis and treatment of lupus. The research also opens new opportunities for developing targeted therapeutic strategies for patients whose disease is associated with abnormal TLR7 signaling.
UNC93B1 Discovery Reveals a Critical TLR7 Control Mechanism
TLR7 is an important immune sensor that helps the body recognize viral infections by detecting genetic material known as RNA. When functioning normally, this receptor helps initiate protective immune responses against invading pathogens. However, excessive TLR7 activity can cause the immune system to mistakenly recognize the body’s own RNA as a threat, potentially triggering autoimmune inflammation. The activity of TLR7 is regulated by UNC93B1, a protein responsible for controlling the movement and function of this immune receptor inside cells. Although abnormal TLR7 signaling has previously been associated with lupus, the precise mechanisms through which UNC93B1 regulates this pathway and prevents autoimmune reactions were not fully understood. In a landmark 2024 study, Gregory Barton and his research team conducted a systematic investigation of UNC93B1 by examining the effects of more than 100 genetic mutations affecting the protein. The researchers identified numerous genetic variants capable of increasing TLR7 activity, including several variants associated with individuals diagnosed with lupus. The team also developed genetically modified mouse models carrying these mutations. The animals developed severe lupus-like autoimmune disease, providing important evidence that disruption of UNC93B1 regulation can directly contribute to excessive immune activation and disease development.
Olivia Majer Uncovers Molecular Cause of Immune Dysfunction
Building on the findings from Barton’s research, Olivia Majer investigated how disease-associated UNC93B1 mutations disrupt immune regulation at the molecular level. Her research focused on a child with early-onset lupus and identified an important mechanism explaining how defective UNC93B1 activity can contribute to abnormal TLR7 signaling. The investigation revealed that UNC93B1 normally interacts with a cellular protein complex known as BORC, which helps ensure that activated TLR7 is appropriately degraded after completing its immune-response function. This process is essential for preventing prolonged or excessive immune signaling. However, a disease-associated UNC93B1 mutation disrupted this regulatory mechanism, allowing TLR7 to accumulate inside immune cells. The resulting increase in receptor activity made the immune system excessively responsive to the body’s own RNA, contributing to autoimmune inflammation. These findings provide a clearer understanding of how genetic abnormalities can interfere with the natural mechanisms responsible for maintaining immune balance. By identifying the molecular relationship between UNC93B1, BORC and TLR7, the researchers have established an important scientific foundation for investigating new approaches to lupus diagnosis and treatment.
Advertisement
Lupus Insight Prize Highlights Future Therapeutic Opportunities
The 2026 Lupus Insight Prize carries a $100,000 award and recognizes recent scientific discoveries with the potential to significantly advance lupus research. The recognition was presented during the newly established Lupus Research Alliance Lupus Insight Prize Lectureship at ACR Convergence 2026, bringing together clinicians, immunologists and researchers to discuss the significance of the findings. Gregory Barton serves as Co-Chair of the Department of Molecular and Cell Biology at the University of California, Berkeley, and is an investigator at the Howard Hughes Medical Institute. Olivia Majer is an Associate Professor of Immunology in the Department of Pediatrics at the University of Cincinnati and leads an immunobiology research laboratory at Cincinnati Children’s. According to Teodora Staeva, PhD, Chief Scientific Officer of the Lupus Research Alliance, the discoveries provide important insight into how the immune system loses its ability to distinguish between foreign threats and the body’s own tissues. The findings could also help researchers identify patients who may benefit from future treatments targeting the TLR7 pathway. The research has important implications for precision medicine and targeted immunotherapy development. Identifying patients with specific UNC93B1 mutations or abnormal TLR7 activity could eventually help guide more individualized treatment strategies. However, additional research and clinical studies will be necessary before these discoveries can translate into approved therapeutic interventions. The recognition highlights the growing importance of understanding the genetic and molecular mechanisms underlying autoimmune diseases. By revealing how defects in immune-regulatory pathways contribute to lupus, the work of Barton and Majer provides a valuable foundation for future research aimed at improving diagnosis, developing targeted treatments and addressing unmet medical needs among people living with lupus.
Source: Lupus Research Alliance press release
